Everolimus-d4A deuterium-labeled derivative of Rapamycin

Everolimus-d4 (CAS 1338452-54-2)

Everolimus-d4 | CAS 1338452-54-2 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_22, h_9
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_218453, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 118ms
  • REVIEWS, PRODUCT
Synonym: 42-O-(2-Hydroxy)ethyl-d4 Rapamycin
Application: A deuterium-labeled derivative of Rapamycin
CAS Number: 1338452-54-2
Molecular Weight: 962.25
Molecular Formula: C53H79D4NO14
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Everolimus-d4 is a Rapamycin derivative and macrolide immunosuppressant. Everolimus-d4 inhibits cytokine-mediated lymphocyte proliferation.


References

Dumont, F.J., et al.: Curr. Opin. Invest. Drugs, 2, 1220 (2001) Kovarik, J. M., et al.: Clin. Pharmacol. Ther., 69, 48 (2001) Nashan, B., et al.: Ther. Drug Monit., 24, 53 (2002)

Physical State :
Solid
Storage :
Store at -20° C
Melting Point :
79-96° C
Boiling Point :
~998.7° C at 760 mmHg (Predicted)
Density :
~1.2 g/cm3 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
SMILES :
[2H]C([2H])(O)C([2H])([2H])O[C@@H]1CC[C@@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)C[C@H]1OC

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Everolimus-d4  Product Citations

See how others have used Everolimus-d4. Click on the entry to view the PubMed entry .

Citations 1 to 2 of 2 total

PMID: # 25077621  Yuan, C. et al. 2014. Bioanalysis. 6: 1597-604.

PMID: # 23503452  Heideloff, C. et al. 2013. Ther Drug Monit. 35: 246-50.

Citations 1 to 2 of 2 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 65ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Heideloff Heideloff, C. et al. (PubMed 23503452) compared the two internal standards (32-desmethoxyrapamycin and Everolimus-d4) for the quantification of everolimus by an LC-MS/MS method. They found that Everolimus-d4 offered a more favorable comparison with an independent LC-MS/MS method. -SCBT Publication Review
Date published: 2015-04-18
  • y_2019, m_9, d_22, h_9
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_218453, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 3ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.